Puma Biotechnology, Inc. (PBYI): Revenue
$228.37M
Year ended 2025-12-31
$231.24M
Trailing 12 months to 2026-06-30
0.0%
3-year compound annual growth
+0.3%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $228.37M | -0.9% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $230.47M | -2.2% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $235.64M | +3.3% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $228.03M | -9.9% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $253.16M | +12.5% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $225.11M | -17.3% | 2023-03-02, From 2020-01-01 |
| 2019-12-31 | $272.26M | +8.5% | 2022-03-03, From 2019-01-01 |
| 2018-12-31 | $250.99M | +806.6% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $27.68M | n/a | 2020-02-28, From 2017-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $228.37M | -0.9% |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $234.60M | +157.0% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $236.20M | +47.5% |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $218.71M | n/m |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $216.10M | +8.7% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $244.06M | n/m |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $213.65M | -6.5% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $247.00M | -4.3% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $255.87M | +23.3% |
Compare PBYI, ANAB, AKBA, IDYA side by side · Screen every company in Pharmaceutical Preparations ↗